Evidence map›Paper›PMID 36701244›Full record

ArticleACS nano2023

Radiolabeled Biodistribution of Expansile Nanoparticles: Intraperitoneal Administration Results in Tumor Specific Accumulation.

Aaron H Colby, Jack Kirsch, Amit N Patwa, Rong Liu, Beth Hollister, William McCulloch, Joanna E Burdette, Cedric J Pearce, Nicholas H Oberliels, Yolonda L Colson and 2 more

Abstract read
In one paragraph

Article in ACS nano, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Tumor-Targeted Delivery Therapy Based on PLGA Nanoparticles.Journal of functional biomaterials · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Aaron H ColbyBoston University, Boston, Massachusetts 02215, United States.ORCID 0000-0001-7161-821X
Jack KirschBoston University, Boston, Massachusetts 02215, United States.
Amit N PatwaBoston University, Boston, Massachusetts 02215, United States.
Rong LiuMassachusetts General Hospital, Boston, Massachusetts 02114, United States.
Beth HollisterHighRock Consulting, Oxford, North Carolina 27565, United States.
William McCullochAlba BioPharm Advisors, Inc., Raleigh, North Carolina 27614, United States.
Joanna E BurdetteUniversity of Illinois at Chicago, Chicago, Illinois 60607, United States.ORCID 0000-0002-7271-6847
Cedric J PearceMycosynthetix, Inc., Hillsborough, North Carolina 27278, United States.
Nicholas H OberlielsIonic Pharmaceuticals, LLC, Watertown, Massachusetts 02472, United States.ORCID 0000-0002-0354-8464
Yolonda L ColsonMassachusetts General Hospital, Boston, Massachusetts 02114, United States.
Kebin LiuAugusta University, Augusta, Georgia 30912, United States.ORCID 0000-0003-1965-7240
Mark W GrinstaffBoston University, Boston, Massachusetts 02215, United States.ORCID 0000-0002-5453-3668

Funding

Pilot Program CoreP30ES027792 · NIEHS · UNIVERSITY OF CHICAGO · PI Gokhan M. Mutlu, Gail S Prins · 2017 to 2026
$13.6M
Translational Research in BiomaterialsT32EB006359 · NIBIB · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI MARK W. GRINSTAFF, Michelle H Teplensky · 2009 to 2026
$4.2M
OPTIMIZATION OF NANOPARTICLE TUMOR-LOCALIZATION AND DRUG-LOADINGFOR TREATING MESOTHELIOMAR01CA232056 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI COLSON, YOLONDA L, GRINSTAFF, MARK W. · 2019 to 2023
$2.7M
TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCER01CA227433 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI COLSON, YOLONDA L, GRINSTAFF, MARK W. · 2018 to 2022
$2.7M
Treating Peritoneal Malignancies with Paclitaxel-Loaded Expansile NanoparticlesR44CA189215 · NCI · IONIC PHARMACEUTICALS · PI COLBY, AARON HENRY · 2019 to 2020
$2.0M
Improving delivery of paclitaxel to ovarian cancer via expansile nanoparticlesR43CA213538 · NCI · IONIC PHARMACEUTICALS · PI COLBY, AARON HENRY · 2017 to 2017
$283k
Large Scale Synthesis and Biodistribution of Expansile NanoparticlesR43CA189215 · NCI · IONIC PHARMACEUTICALS · PI COLBY, AARON HENRY · 2014 to 2014
$225k
CSRD VA I01 CX001364NCI NIH HHS R01 CA227433NCI NIH HHS R01 CA232056NCI NIH HHS R43 CA189215NCI NIH HHS R43 CA213538NCI NIH HHS R44 CA189215NIBIB NIH HHS T32 EB006359NIEHS NIH HHS P30 ES027792
6 · The paper itself

Abstract

Nanoparticle biodistribution

Indexed as

MesotheliomaMesothelioma, MalignantNanoparticlesAnimalsHumansInjections, IntraperitonealMiceTissue Distributionexpansile nanoparticleintraperitoneal administrationliquid scintillation countingmaterials-based targetingRadiolabeled biodistribution

Identifiers

PMID36701244
PMCPMC9933882

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.